Covid19NCT07074184
Radiofrequency Intervention in Post-COVID-19 Patients With Musculoskeletal Sequelae
A study testing Radiofrequency 448khz with manual therapy, Turn off radiofrequency 448khz and Manual therapy in people with Covid19 and Musculoskeletal Injury, run by Clinica Gema Leon at 1 site in Spain.
Trial summary
The sequelae that occur in post-COVID-19 patients are multiple and, at a therapeutic level, these represent a new challenge within the general context of the pandemic that the world is suffering. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Covid19, Musculoskeletal Injury
- What is being tested?
- Radiofrequency 448khz with manual therapy, Turn off radiofrequency 448khz and Manual therapy
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 99 participants
- Where
- 1 siteSpain
- Study dates
- 16 Jun 2021to 20 Jul 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients between the ages of 18 and 60.
- Patients with a positive diagnosis of COVID-19.
- Patients with post-COVID-19 sequelae with elbow musculoskeletal diseases.
- Patients who signed the informed consent.
Who cannot join
- Patients aged before 18 years and after 60 years.
- Healthy people with no history of elbow musculoskeletal diseases
- Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Gema León Physiotherapy and Rehabilitation Clinic
Córdoba, Andalusia, 14011
About this study
Official title: Radiofrequency Intervention in Musculoskeletal Pathologies Post COVID-19
The sequelae that occur in post-COVID-19 patients are multiple and, at a therapeutic level, these represent a new challenge within the general context of the pandemic that the world is suffering.
The virus has managed to end thousands of lives today and many other cases are being charged as directly responsible for a multiplicity of multisystem damages that need to be diagnosed and treated. Among the most relevant, are those that can affect to levels musculoskeletal in patients without previous pathologies, and in patients at risk who already had a pathology prior to infection.
Read more
On the other hand, signs and symptoms have been observed characteristic in the organ systems described above in post-contagion patients, directly associated with sequelae SARV-CoV2. The radiofrequency (RF) of electromagnetic waves represents a technology of proven efficacy and safety in multiple fields of both human and veterinary medicine. These include neurological and pneumological pathologies, and very especially those that affect the locomotor system. In therapeutics there are different RF modalities depending on the modality, polarity, type of signal and frequency, which in turn translate into different therapeutic profiles, clinical indications, efficacy and safety.
Among the RF technologies most used today and that have a greater scientific background, is the one known as Resistive Capacitive Monopolar Radio Frequency at 448 kHz (INDIBA®). This study aims to assess the efficacy and safety of RFMCR in the treatment of musculoskeletal sequelae in patients presenting this type of pathologies that appear after contagion by COVID-19. Through this non-invasive technique, the investigators want to show that RF can help the physical rehabilitation of these patients through metabolic stimulation, increased vascularization and oxygenation of directly affected tissues, effects of deep hyperthermia generated by the interaction of the current with the treated biological substrate, as well as the activation of tissue regeneration, the result of subthermal action. It is thus intended to improve signs such as global muscle capacity, which is essential for the recovery of the post-COVID-19 patients.
The hypothesis of this study is that current post-COVID-19 treatments can be significantly improved in order to prevent complications and ensure the patients' well-being.
Read the detailed description
The new post-pandemic era has left sequelae in patients who presented the signs and symptoms of SARV-CoV2 and subsequently faced a positive for COVID-19. Such sequelae will be evident at various systemic levels of the affected patienta in the short, medium and long term future. One of these levels is musculoskeletal complications and injuries that have been documented throughout all scientific research since the beginning of massive infections worldwide.
SARS-CoV-2 is transmitted by penetrating the respiratory route (mostly), by fluid contact, and to a lesser extent, through the ocular pathway. In the field of neurology system, different forms of RF, nerve infiltrations, lymph node injuries, plantar fasciitis, spinal (peripheral) nerve disorders, etc. have been documented.
If the investigators focus on one of the most prevalent symptoms (those that affect the respiratory system), the bibliography that endorses that the RF could improve has been referenced.
The aim of this study is to assess the potential benefits of RF in patients with musculoskeletal problems which started after SARV-CoV-2 infection. The work proposed here aims to demonstrate the advantages of establishing RF as an excellent treatment for post-COVID-19 sequelae, due to its ability to reinforce immune action, modulate the inflammatory response and activate cellular and tissue regeneration.
The specific objectives of this research work are:
To demonstrate the efficacy of RF as a therapy in musculoskeletal pathologies derived from the sequelae of COVID-19.
To evidence and document the effects generated by the treatment with RF in the musculoskeletal system.
To estimate the level of benefit from RF in the musculoskeletal system treated and define the benefit/risk ratio.
To present and validate the therapy for the injuries under study that show significant improvements.
REGULATIONS
This clinical study will be carried out in accordance with the protocol, the principles established in the current revised version of the Declaration of Helsinki (Fortaleza, 2013) and in accordance with the applicable regulatory requirements.
The researcher is aware, when signing the protocol, of the obligation to adhere to the instructions and procedures described in it, and will ensure that the established provisions are strictly adhered to.
The study will not begin until the approval of the Research Ethics Committee has been obtained.
The principal investigator is responsible for ensuring that this protocol, the informed consent document, and any other information that is presented or facilitated to the possible subjects is reviewed and approved by the CEI. The Researcher agrees to allow direct access to the REC to all relevant documents.
INFORMED CONSENT.
In this case, patients must give their consent prior to being included in the study. The content and the procedure for obtaining it must be in accordance with all applicable legal requirements.
The investigator is responsible for obtaining the written informed consent of each patient participating in this study, after having explained in an understandable way, the nature, objectives, methods, expected benefits and possible risks of the study. The investigator must also explain to them that patients are completely free to refuse to participate in the study or to withdraw from it at any time, for whatever reason.
The study patients will give their consent, signing the corresponding model. For this purpose, each informed consent must be signed by both the investigator and the patient.
CONFIDENTIALITY.
All information related to the study is considered confidential in compliance with the confidentiality and custody of the data collected, in accordance with the 3/2018 Law on the protection of personal data (LOPDGDD), (article 5). Article 5.1 .f) of the RGPD states that personal data will be treated in such a way as to guarantee confidentiality and integrity In order to guarantee the confidentiality of the study data, only the main researcher and her team of collaborators will have access to it, the CEI and the pertinent health authorities.
FINANCING
The financing is assumed by the Gema León Physiotherapy and Rehabilitation Clinic. There is no direct economic consideration for this, although there is a dedication of time and work by the team of physiotherapists (social security, payroll, personal income tax, etc.) that is not economically remunerated and is assumed or absorbed this way. In addition, the RF technology (equipment and accessories) will be provided by the company INDIBA S.A., through a temporary assignment without any financial compensation either from the Gema León Physiotherapy Clinic, or from any patient. The treatment of these is completely free for them.
The patient must travel to the clinic facilities and it is the researcher who will be responsible for the treatment in it.
No difficulties are foreseen in its performance since it will be carried out using a schedule adapted to the patient that allows the study to be monitored.
It is intended to carry out a longitudinal study with the participation of 99 patients with elbow musculoskeletal pathology, who confirmed a positive test for COVID-19. The sample size for our study is large enough to detect a clinically important difference in the primary outcome (s). For this, the investigators reviewed references at the bibliographic level, in which paired studies obtained a statistically significant value, being able to support our study. If the sample size was insufficient but statistically significant, the investigators would resort to expanding the sample. The division of the sample is carried out at random within the established groups.
The patients will be divided into three groups: Group A or Placebo Group, which received the treatment with the machine turned off. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off. Group B or Mixed Group, treatment with manual therapy and radiofrequency. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment.Group C or Manual Group, to which conventional manual therapy was applied for each case. Articulatory pumping techniques were applied towards the painful position with the aim of reducing it.
Thus we compare the therapies of groups A, B and C, of Musculoskeletal Pathologies.
All groups will be evaluated at the beginning, a second evaluation after 3 weeks and a third final control after 12 sessions. A fourth evaluation will be carried out after the last and final evaluation, 6 weeks after finishing the treatment. Each of the participants will be informed of the study, the objective, its possible benefits and the side effects that could arise. A) Therefore, each patient must give their free and confirmed consent through signature. Among the items in the methodology, the following stand out:
Primary data parameters: A series of questions will be asked to each of the patients about the conditions diagnosed during the disease and those suffered after the infection that are directly related to abnormalities to be assessed.
Secondary Data Parameters: The therapeutic protocol will be executed in the facilities of the Gema León Physiotherapy and Rehabilitation Clinic (Cordoba, Spain). Such RF therapeutic protocol will be implemented by application with an INDIBA® Activ device, whose function is to reduce inflammation, stimulate immunity and promote tissue regeneration. This will consist of a 30-minute treatment, composed by 5 minutes of treatment with the capacitive electrode and 25 minutes of the resistive electrode. A total of 12 sessions will be scheduled (two per week), and all processes will be documented from the beginning of therapy (the resources used will be provided by INDIBA and the Gema León Physiotherapy and Rehabilitation Clinic, whose supervision will be carried out by the direction of both).
Dependent Variables: variables of nominal type such as sex, age, vaccination, number of days with symptoms, type of symptom will be created. The patients will be grouped into 3 groups of 33 participants each (99 in total):
Placebo Group, which received the treatment with the machine turned off. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off.
Experimental Mixed Group, treatment with manual therapy and radiofrequency. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment.
Convencional Manual Group, to which conventional manual therapy was applied for each case. Articulatory pumping techniques were applied towards the painful position with the aim of reducing it.
Independent Variables: In order to compare the variables between groups, different methods of pain threshold and function of the mentioned systems will be used, such as: Global Functionality Scale (GAF), Katz Index for Independence, Lawton and Brody Scale of Basic Activities, Barthel index for disability, European Quality of Life 5-D Questionnaire (EURO- QoL 5-D) for quality of life, Tinetti test for gait and balance, joint amplitude scale measured with the goniometer (goniometry), strength muscle dynamometer (Dynamometry), pain index (Visual Analogue Scale (VAS), reflectivity measurement with the Wartenberg Scale for bone tendon reflexes (ROTs), examination of sensitivity from evaluation of dermatomes. The statistical analysis is based on variables of nominal type mostly, which are suitable for the Chi square test with a significance value of 95% for the results (p <0.05). However, if there are numerical data that must be compared between groups, the analysis will be used for ANOVA test with the same significance value for the comparison between results.
- Conditions
- Covid19, Musculoskeletal Injury
- Being tested
- Radiofrequency 448khz with manual therapy, Turn off radiofrequency 448khz, Manual therapy
- Keywords
- COVID-19
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Radiofrequency 448khz with manual therapyOther
The intervention in consisted of a total of 12 sessions (twice a week) of treatment. The set duration for each session was 45 minutes, except for those sessions where variable measurements were required, which lasted 60 minutes. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment.
Turn off radiofrequency 448khzOther
Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off.
Manual therapyOther
Articulatory pumping techniques were applied towards the painful position with the aim of reducing it.
| Study group | Role | What they receive |
|---|---|---|
| Placebo group | Placebo comparator | Placebo Group: Patient receiving treatment with radiofrequency turned off Receives: Other: Turn off radiofrequency 448khz |
| Treatment group | Experimental | Experimental Mixed Group: Patient receiving treatment with manual therapy and radiofrequency; Receives: Other: Radiofrequency 448khz with manual therapy |
| Conventional group | Active comparator | Convencional Manual Group: Patient receiving treatment with manual therapy Receives: Other: Manual therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Joint range of motion was measured
Measurements were taken using a goniometer of at least two joint movement axes in each casMeasurements were taken using a goniometer of at least two joint movement axes in each case
Measured: 3 months
A muscle assessment was performed.
Strength measurements were taken using a dynamometer. The peak torque during a 5-second concentric contraction was measured. This contraction was repeated a total of three times, with the average of the three measurements taken as the final result.
Measured: 3 months
Secondary outcomes (4)
Upper Limb Functional Index questionnaire
A total of 20 questions with responses ranging from 0 to 4. Optimal total score: 80. Minimum score: 0. Maximum score: 80.
Measured: 3 months
Lower Extremity Functional Scale for the lower limb.
25 questions with responses ranging from 0 to 4. Optimal total score: 100. Minimum score: 0. Maximum score: 100.
Measured: 3 months
Visual Analogue Scale for pain (VAS)
which allows for the classification of the patient's pain on a scale from 0 (no pain) to 10 (unbearable pain)
Measured: 3 months
Patient independence (Katz Index)
Questions about activities of daily living were provided. Minimum value: 0 (ability to perform basic activities of daily living). Maximum value: 1 (inability to perform basic activities of daily living). Optimal value: 0.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2025
- Study start16 Jun 2021
- Primary completion21 Jun 2022
- Study completion20 Jul 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 99 participants (actual)
Sponsor and investigators
- Lead sponsor
- Clinica Gema Leon
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, GEMA LEÓN BRAVO, Clinica Gema Leon
- Investigators
- Gema Leon Bravo, Principal investigator, Departamento de Enfermería, Farmacología y Fisioterapia de la Universidad de Córdoba
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07074184
- Sponsor's protocol ID
- ART-GLB-RF-MUSC-COVID
- Status last verified
- Aug 2025
- First submitted
- 16 Jul 2025
- Last updated
- 29 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The request for the data will be studied and considered upon prior and justified request.
Publications
Bito T, Tashiro Y, Suzuki Y, Kajiwara Y, Zeidan H, Kawagoe M, Sonoda T, Nakayama Y, Yokota Y, Shimoura K, Tatsumi M, Nakai K, Nishida Y, Yoshimi S, Tsuboyama T, Aoyama T. Acute effects of capacitive and resistive electric transfer (CRet) on the Achilles tendon. Electromagn Biol Med. 2019;38(1):48-54. doi: 10.1080/15368378.2019.1567525. Epub 2019 Jan 19.
PubMed 30663425Tashiro Y, Hasegawa S, Yokota Y, Nishiguchi S, Fukutani N, Shirooka H, Tasaka S, Matsushita T, Matsubara K, Nakayama Y, Sonoda T, Tsuboyama T, Aoyama T. Effect of Capacitive and Resistive electric transfer on haemoglobin saturation and tissue temperature. Int J Hyperthermia. 2017 Sep;33(6):696-702. doi: 10.1080/02656736.2017.1289252. Epub 2017 Feb 19.
PubMed 28139939Arena M. Radiofrequency A 448 kHz in the treatment of muscle spasticity in a dog with C2-C3 spinal cord injury. 2018. 12-3.
Erdine S, Ozyalcin NS, Cimen A, Celik M, Talu GK, Disci R. Comparison of pulsed radiofrequency with conventional radiofrequency in the treatment of idiopathic trigeminal neuralgia. Eur J Pain. 2007 Apr;11(3):309-13. doi: 10.1016/j.ejpain.2006.04.001. Epub 2006 Jun 9.
PubMed 16762570Pérez-Cajaraville J., Aseguinolaza Pagola M., Molina Tresaco P., Arranz Duran J., Abejon Gonzalez D.. Trigeminal neuralgia: Gasser ganglion radiofrecuency. Rev. Soc. Esp. Dolor [Internet]. 2013 Apr [cited 2025 July 16] ; 20( 2 ): 89-100. Available from: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1134-80462013000200007&lng=en. https://dx.doi.org/10.4321/S1134-80462013000200007.
Martínez Rubio A, Bordas JR. Treatment of asthma by capacitive electrical transfer (ECT). Rehab Fis. 1992; 3 (13): 18-9.
Alves A, Quispe A, Ávila A, Valdivia A, Chino J, Vera O. Brief history and pathophysiology of COVID-19. Diagnostic Guide and COVID-19 Treatment in Ter Intensive Units for Boliv [Internet]. 2020; 61 (1): 77-86.
Bito T, Suzuki Y, Kajiwara Y, Zeidan H, Harada K, Shimoura K, Tatsumi M, Nakai K, Nishida Y, Yoshimi S, Kawabe R, Yokota J, Yamashiro C, Tsuboyama T, Aoyama T. Effects of deep thermotherapy on chest wall mobility of healthy elderly women. Electromagn Biol Med. 2020 Apr 2;39(2):123-128. doi: 10.1080/15368378.2020.1737803. Epub 2020 Mar 4.
PubMed 32131642
Study at a glance
From the registry record, last updated by the sponsor on 29 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radiofrequency Intervention in Musculoskeletal Pathologies Post COVID-19
- ClinicalTrials.gov ID
- NCT07074184
- Acronym / sponsor ID
- ART-GLB-RF-MUSC-COVID
- Conditions
- Covid19, Musculoskeletal Injury
- Keywords
- COVID-19
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 99 participants (actual)
- Lead sponsor
- Clinica Gema LeonUniversity, hospital or other
- Study start
- 16 Jun 2021 (actual)
- Primary completion
- 21 Jun 2022 (actual)
- Study completion
- 20 Jul 2022 (actual)
- First posted
- 20 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The sequelae that occur in post-COVID-19 patients are multiple and, at a therapeutic level, these represent a new challenge within the general context of the pandemic that the world is suffering.
The virus has managed to end thousands of lives today and many other cases are being charged as directly responsible for a multiplicity of multisystem damages that need to be diagnosed and treated. Among the most relevant, are those that can affect to levels musculoskeletal in patients without previous pathologies, and in patients at risk who already had a pathology prior to infection.
On the other hand, signs and symptoms have been observed characteristic in the organ systems described above in post-contagion patients, directly associated with sequelae SARV-CoV2. The radiofrequency (RF) of electromagnetic waves represents a technology of proven efficacy and safety in multiple fields of both human and veterinary medicine. These include neurological and pneumological pathologies, and very especially those that affect the locomotor system. In therapeutics there are different RF modalities depending on the modality, polarity, type of signal and frequency, which in turn translate into different therapeutic profiles, clinical indications, efficacy and safety.
Among the RF technologies most used today and that have a greater scientific background, is the one known as Resistive Capacitive Monopolar Radio Frequency at 448 kHz (INDIBA®). This study aims to assess the efficacy and safety of RFMCR in the treatment of musculoskeletal sequelae in patients presenting this type of pathologies that appear after contagion by COVID-19. Through this non-invasive technique, the investigators want to show that RF can help the physical rehabilitation of these patients through metabolic stimulation, increased vascularization and oxygenation of directly affected tissues, effects of deep hyperthermia generated by the interaction of the current with the treated biological substrate, as well as the activation of tissue regeneration, the result of subthermal action. It is thus intended to improve signs such as global muscle capacity, which is essential for the recovery of the post-COVID-19 patients.
The hypothesis of this study is that current post-COVID-19 treatments can be significantly improved in order to prevent complications and ensure the patients' well-being.
Detailed description
The new post-pandemic era has left sequelae in patients who presented the signs and symptoms of SARV-CoV2 and subsequently faced a positive for COVID-19. Such sequelae will be evident at various systemic levels of the affected patienta in the short, medium and long term future. One of these levels is musculoskeletal complications and injuries that have been documented throughout all scientific research since the beginning of massive infections worldwide.
SARS-CoV-2 is transmitted by penetrating the respiratory route (mostly), by fluid contact, and to a lesser extent, through the ocular pathway. In the field of neurology system, different forms of RF, nerve infiltrations, lymph node injuries, plantar fasciitis, spinal (peripheral) nerve disorders, etc. have been documented.
If the investigators focus on one of the most prevalent symptoms (those that affect the respiratory system), the bibliography that endorses that the RF could improve has been referenced.
The aim of this study is to assess the potential benefits of RF in patients with musculoskeletal problems which started after SARV-CoV-2 infection. The work proposed here aims to demonstrate the advantages of establishing RF as an excellent treatment for post-COVID-19 sequelae, due to its ability to reinforce immune action, modulate the inflammatory response and activate cellular and tissue regeneration.
The specific objectives of this research work are:
To demonstrate the efficacy of RF as a therapy in musculoskeletal pathologies derived from the sequelae of COVID-19.
To evidence and document the effects generated by the treatment with RF in the musculoskeletal system.
To estimate the level of benefit from RF in the musculoskeletal system treated and define the benefit/risk ratio.
To present and validate the therapy for the injuries under study that show significant improvements.
REGULATIONS
This clinical study will be carried out in accordance with the protocol, the principles established in the current revised version of the Declaration of Helsinki (Fortaleza, 2013) and in accordance with the applicable regulatory requirements.
The researcher is aware, when signing the protocol, of the obligation to adhere to the instructions and procedures described in it, and will ensure that the established provisions are strictly adhered to.
The study will not begin until the approval of the Research Ethics Committee has been obtained.
The principal investigator is responsible for ensuring that this protocol, the informed consent document, and any other information that is presented or facilitated to the possible subjects is reviewed and approved by the CEI. The Researcher agrees to allow direct access to the REC to all relevant documents.
INFORMED CONSENT.
In this case, patients must give their consent prior to being included in the study. The content and the procedure for obtaining it must be in accordance with all applicable legal requirements.
The investigator is responsible for obtaining the written informed consent of each patient participating in this study, after having explained in an understandable way, the nature, objectives, methods, expected benefits and possible risks of the study. The investigator must also explain to them that patients are completely free to refuse to participate in the study or to withdraw from it at any time, for whatever reason.
The study patients will give their consent, signing the corresponding model. For this purpose, each informed consent must be signed by both the investigator and the patient.
CONFIDENTIALITY.
All information related to the study is considered confidential in compliance with the confidentiality and custody of the data collected, in accordance with the 3/2018 Law on the protection of personal data (LOPDGDD), (article 5). Article 5.1 .f) of the RGPD states that personal data will be treated in such a way as to guarantee confidentiality and integrity In order to guarantee the confidentiality of the study data, only the main researcher and her team of collaborators will have access to it, the CEI and the pertinent health authorities.
FINANCING
The financing is assumed by the Gema León Physiotherapy and Rehabilitation Clinic. There is no direct economic consideration for this, although there is a dedication of time and work by the team of physiotherapists (social security, payroll, personal income tax, etc.) that is not economically remunerated and is assumed or absorbed this way. In addition, the RF technology (equipment and accessories) will be provided by the company INDIBA S.A., through a temporary assignment without any financial compensation either from the Gema León Physiotherapy Clinic, or from any patient. The treatment of these is completely free for them.
The patient must travel to the clinic facilities and it is the researcher who will be responsible for the treatment in it.
No difficulties are foreseen in its performance since it will be carried out using a schedule adapted to the patient that allows the study to be monitored.
It is intended to carry out a longitudinal study with the participation of 99 patients with elbow musculoskeletal pathology, who confirmed a positive test for COVID-19. The sample size for our study is large enough to detect a clinically important difference in the primary outcome (s). For this, the investigators reviewed references at the bibliographic level, in which paired studies obtained a statistically significant value, being able to support our study. If the sample size was insufficient but statistically significant, the investigators would resort to expanding the sample. The division of the sample is carried out at random within the established groups.
The patients will be divided into three groups: Group A or Placebo Group, which received the treatment with the machine turned off. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off. Group B or Mixed Group, treatment with manual therapy and radiofrequency. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment.Group C or Manual Group, to which conventional manual therapy was applied for each case. Articulatory pumping techniques were applied towards the painful position with the aim of reducing it.
Thus we compare the therapies of groups A, B and C, of Musculoskeletal Pathologies.
All groups will be evaluated at the beginning, a second evaluation after 3 weeks and a third final control after 12 sessions. A fourth evaluation will be carried out after the last and final evaluation, 6 weeks after finishing the treatment. Each of the participants will be informed of the study, the objective, its possible benefits and the side effects that could arise. A) Therefore, each patient must give their free and confirmed consent through signature. Among the items in the methodology, the following stand out:
Primary data parameters: A series of questions will be asked to each of the patients about the conditions diagnosed during the disease and those suffered after the infection that are directly related to abnormalities to be assessed.
Secondary Data Parameters: The therapeutic protocol will be executed in the facilities of the Gema León Physiotherapy and Rehabilitation Clinic (Cordoba, Spain). Such RF therapeutic protocol will be implemented by application with an INDIBA® Activ device, whose function is to reduce inflammation, stimulate immunity and promote tissue regeneration. This will consist of a 30-minute treatment, composed by 5 minutes of treatment with the capacitive electrode and 25 minutes of the resistive electrode. A total of 12 sessions will be scheduled (two per week), and all processes will be documented from the beginning of therapy (the resources used will be provided by INDIBA and the Gema León Physiotherapy and Rehabilitation Clinic, whose supervision will be carried out by the direction of both).
Dependent Variables: variables of nominal type such as sex, age, vaccination, number of days with symptoms, type of symptom will be created. The patients will be grouped into 3 groups of 33 participants each (99 in total):
Placebo Group, which received the treatment with the machine turned off. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off.
Experimental Mixed Group, treatment with manual therapy and radiofrequency. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment.
Convencional Manual Group, to which conventional manual therapy was applied for each case. Articulatory pumping techniques were applied towards the painful position with the aim of reducing it.
Independent Variables: In order to compare the variables between groups, different methods of pain threshold and function of the mentioned systems will be used, such as: Global Functionality Scale (GAF), Katz Index for Independence, Lawton and Brody Scale of Basic Activities, Barthel index for disability, European Quality of Life 5-D Questionnaire (EURO- QoL 5-D) for quality of life, Tinetti test for gait and balance, joint amplitude scale measured with the goniometer (goniometry), strength muscle dynamometer (Dynamometry), pain index (Visual Analogue Scale (VAS), reflectivity measurement with the Wartenberg Scale for bone tendon reflexes (ROTs), examination of sensitivity from evaluation of dermatomes. The statistical analysis is based on variables of nominal type mostly, which are suitable for the Chi square test with a significance value of 95% for the results (p <0.05). However, if there are numerical data that must be compared between groups, the analysis will be used for ANOVA test with the same significance value for the comparison between results.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Placebo group | Placebo comparator | Other: Turn off radiofrequency 448khzPlacebo Group: Patient receiving treatment with radiofrequency turned off |
| Treatment group | Experimental | Other: Radiofrequency 448khz with manual therapyExperimental Mixed Group: Patient receiving treatment with manual therapy and radiofrequency; |
| Conventional group | Active comparator | Other: Manual therapyConvencional Manual Group: Patient receiving treatment with manual therapy |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Patients between the ages of 18 and 60.
- Patients with a positive diagnosis of COVID-19.
- Patients with post-COVID-19 sequelae with elbow musculoskeletal diseases.
- Patients who signed the informed consent.
Key exclusion criteria (3 listed)
- Patients aged before 18 years and after 60 years.
- Healthy people with no history of elbow musculoskeletal diseases
- Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Radiofrequency 448khz with manual therapyThe intervention in consisted of a total of 12 sessions (twice a week) of treatment. The set duration for each session was 45 minutes, except for those sessions where variable measurements were required, which lasted 60 minutes. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment. | Other | Treatment group |
| Turn off radiofrequency 448khzRadiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off. | Other | Placebo group |
| Manual therapyArticulatory pumping techniques were applied towards the painful position with the aim of reducing it. | Other | Conventional group |
Primary outcome
Joint range of motion was measured
Time frame: 3 months
Measurements were taken using a goniometer of at least two joint movement axes in each casMeasurements were taken using a goniometer of at least two joint movement axes in each case
A muscle assessment was performed.
Time frame: 3 months
Strength measurements were taken using a dynamometer. The peak torque during a 5-second concentric contraction was measured. This contraction was repeated a total of three times, with the average of the three measurements taken as the final result.
4 secondary outcomes
Upper Limb Functional Index questionnaire
Time frame: 3 months
Lower Extremity Functional Scale for the lower limb.
Time frame: 3 months
Visual Analogue Scale for pain (VAS)
Time frame: 3 months
Patient independence (Katz Index)
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Aug 2025.
- Background: PubMed 30663425Bito T, Tashiro Y, Suzuki Y, Kajiwara Y, Zeidan H, Kawagoe M, Sonoda T, Nakayama Y, Yokota Y, Shimoura K, Tatsumi M, Nakai K, Nishida Y, Yoshimi S, Tsuboyama T, Aoyama T. Acute effects of capacitive and resistive electric transfer (CRet) on the Achilles tendon. Electromagn Biol Med. 2019;38(1):48-54. doi: 10.1080/15368378.2019.1567525. Epub 2019 Jan 19.
- Background: PubMed 28139939Tashiro Y, Hasegawa S, Yokota Y, Nishiguchi S, Fukutani N, Shirooka H, Tasaka S, Matsushita T, Matsubara K, Nakayama Y, Sonoda T, Tsuboyama T, Aoyama T. Effect of Capacitive and Resistive electric transfer on haemoglobin saturation and tissue temperature. Int J Hyperthermia. 2017 Sep;33(6):696-702. doi: 10.1080/02656736.2017.1289252. Epub 2017 Feb 19.
- BackgroundArena M. Radiofrequency A 448 kHz in the treatment of muscle spasticity in a dog with C2-C3 spinal cord injury. 2018. 12-3.
- Background: PubMed 16762570Erdine S, Ozyalcin NS, Cimen A, Celik M, Talu GK, Disci R. Comparison of pulsed radiofrequency with conventional radiofrequency in the treatment of idiopathic trigeminal neuralgia. Eur J Pain. 2007 Apr;11(3):309-13. doi: 10.1016/j.ejpain.2006.04.001. Epub 2006 Jun 9.
- BackgroundPérez-Cajaraville J., Aseguinolaza Pagola M., Molina Tresaco P., Arranz Duran J., Abejon Gonzalez D.. Trigeminal neuralgia: Gasser ganglion radiofrecuency. Rev. Soc. Esp. Dolor [Internet]. 2013 Apr [cited 2025 July 16] ; 20( 2 ): 89-100. Available from: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1134-80462013000200007&lng=en. https://dx.doi.org/10.4321/S1134-80462013000200007.
- BackgroundMartínez Rubio A, Bordas JR. Treatment of asthma by capacitive electrical transfer (ECT). Rehab Fis. 1992; 3 (13): 18-9.
- BackgroundAlves A, Quispe A, Ávila A, Valdivia A, Chino J, Vera O. Brief history and pathophysiology of COVID-19. Diagnostic Guide and COVID-19 Treatment in Ter Intensive Units for Boliv [Internet]. 2020; 61 (1): 77-86.
- Results publication: PubMed 32131642Bito T, Suzuki Y, Kajiwara Y, Zeidan H, Harada K, Shimoura K, Tatsumi M, Nakai K, Nishida Y, Yoshimi S, Kawabe R, Yokota J, Yamashiro C, Tsuboyama T, Aoyama T. Effects of deep thermotherapy on chest wall mobility of healthy elderly women. Electromagn Biol Med. 2020 Apr 2;39(2):123-128. doi: 10.1080/15368378.2020.1737803. Epub 2020 Mar 4.
- Individual participant dataSharing planned: No. The request for the data will be studied and considered upon prior and justified request.
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gema Leon Bravo principal investigator
Departamento de Enfermería, Farmacología y Fisioterapia de la Universidad de Córdoba
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Radiofrequency 448khz with manual therapy, Turn off radiofrequency 448khz and Manual therapy in people with Covid19 and Musculoskeletal Injury, run by Clinica Gema Leon at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Joint range of motion was measured (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07074184, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Aug 2025.